Association of Baseline Spinal Cord Area and Brain Volume With Long-Term Disability Progression in Ozanimod-Treated Participants With Relapsing Multiple Sclerosis: Final Analysis From the DAYBREAK Open-label Extension Study

被引：0

作者：

Filippi, Massimo ^{[1
,2
]}

Henry, Roland ^{[3
]}

Arnold, Douglas ^{[4
,5
]}

Granziera, Cristina ^{[6
,7
,8
,9
,10
,11
,12
,13
,14
]}

Kappos, Ludwig ^{[9
,10
,11
,12
,13
,14
]}

Sheffield, James ^{[15
]}

Cheng, Chun-Yen ^{[15
]}

Riolo, Jon ^{[15
]}

Pachai, Chahin ^{[15
]}

Cree, Bruce A. C. ^{[3
]}

机构：

[1] IRCCS San Raffaele Sci Inst, Neurol Unit, Div Neurosci, Neuroimaging Res Unit,Neurorehabil Unit, Milan, Italy

[2] Univ Vita Salute San Raffaele, Neurophysiol Serv, Milan, Italy

[3] Univ Calif San Francisco, Dept Neurol, Weill Inst Neurosci, San Francisco, CA USA

[4] McGill Univ, NeuroRx Res, Montreal, PQ, Canada

[5] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada

[6] Univ Hosp Basel, Dept Biomed Engn, Translat Imaging Neurol ThINk Basel, Fac Med, Basel, Switzerland

[7] Univ Basel, Basel, Switzerland

[8] Univ Hosp Basel, Dept Neurol, Basel, Switzerland

[9] Univ Hosp, Dept Headorgans Spine & Neuromed, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Basel, Switzerland

[10] Univ Hosp, Dept Headorgans Spine & Neuromed, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Basel, Switzerland

[11] Univ Hosp, Dept Clin Res, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Basel, Switzerland

[12] Univ Hosp, Dept Biomed, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Basel, Switzerland

[13] Univ Hosp, Dept Biomed Engn, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Basel, Switzerland

[14] Univ Basel, Basel, Switzerland

[15] Bristol Myers Squibb, Princeton, NJ USA

来源：

MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P1451/510

引用

页码：922 / 923

页数：2

共 43 条

[21] Long-term Safety and Tolerability of Ozanimod by Age Category in Patients With Relapsing Multiple Sclerosis From Two Phase 3 Trials and an Open-Label Extension Study
Selmaj, K. W.
Cohen, J. A.
Steinman, L.
Comi, G.
Bar-Or, A.
Hartung, H.
Montalban, X.
Kappos, L.
Sheffield, J. K.
Krakovich, A.
Cheng, C.
Riolo, J.
Silva, D.
Cree, B. A.
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 56 - 57
[22] Long-term Efficacy of Ozanimod by Age Category in Patients With Relapsing Multiple Sclerosis in Two Phase 3 Trials and an Open-label Extension Trial
Cree, B. A.
Selmaj, K.
Steinman, L.
Comi, G.
Bar-Or, A.
Arnold, D. L.
Hartung, H.
Montalban, X.
Havrdova, E. K.
Sheffield, J. K.
Cheng, C.
Riolo, J. V.
Silva, D.
Kappos, L.
Cohen, J. A.
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 55 - 56
[23] Whole Brain, Cortical Grey Matter, and Thalamic Volume Changes During 5-7 Years of Ozanimod in Relapsing MS: Final Results From the DAYBREAK Open-Label Extension Study
Cohen, Jeffrey
Arnold, Douglas
DeLuca, John
Hartung, Hans-Peter
Kappos, Ludwig
Comi, Giancarlo
Selmaj, Krzysztof
Steinman, Lawrence
Bar-Or, Amit
Montalban, Xavier
Havrdova, Eva
Sheffield, James
Pachai, Chahin
Cheng, Chun-Yen
Riolo, Jon
Cree, Bruce A. C.
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1027 - 1029
[24] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial (vol 28, pg 1944, 2022)
不详
MULTIPLE SCLEROSIS JOURNAL, 2022,
[25] Correlations Between Early MRI Parameters and Long-term Clinical Outcomes in Phase 3 and Open-label Extension Studies of Ozanimod in Relapsing Multiple Sclerosis
Arnold, Douglas L.
Freeman, Leorah
Hartung, Hans-Peter
Montalban, Xavier
Cohen, Jeffrey A.
Bar-Or, Amit
Steinman, Lawrence
DeLuca, John
Cheng, Chun-Yen
Riolo, Jon V.
Silva, Diego
Pachai, Chahin
Cree, Bruce A. C.
NEUROLOGY, 2023, 100 (17)
[26] Correlations between early MRI parameters and long-term clinical outcomes in phase 3 and open-label extension studies of ozanimod in relapsing multiple sclerosis
Arnold, D. L.
Freeman, L.
Hartung, H. -P.
Xavier Montalban, X.
Cohen, J. A.
Bar-Or, A.
Steinman, L.
DeLuca, J.
Cheng, C. -Y.
Riolo, J. V.
Silva, D.
Pachai, C.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 377 - 378
[27] Safety of Evobrutinib in Patients With Relapsing Multiple Sclerosis is Maintained in a Long-term Open-label Extension of a Phase II Study
Montalban, Xavier
Arnold, Douglas L.
Weber, Martin S.
Staikov, Ivan
Piasecka-Stryczynska, Karolina
Martin, Emily C.
Mandel, Matthew
Zima, Yulia
Shaw, Jamie
Dangond, Fernando
Grenningloh, Roland
Li, Ying
Tomic, Davorka
Wolinsky, Jerry S.
NEUROLOGY, 2021, 96 (15)
[28] Long-Term Progression Independent of Relapse Activity Rates and Associated Prediction Model Based on Machine Learning in Phase 3 and Open-Label Extension Studies of Ozanimod in Relapsing Multiple Sclerosis
Kappos, Ludwig
Arnold, Douglas
Pachai, Chahin
Eddy, Nathanial
Osik, Jason
Cheng, Chun-Yen
Harris, Sarah
Riolo, Jon
Thorpe, Andrew
DeBoer, Erik
Freeman, Leorah
Granziera, Cristina
Filippi, Massimo
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1150 - 1152
[29] VISIONARY-MS Long-Term Extension: A Multicenter, Open-Label, Long-Term Extension Study of CNM-Au8 in Patients With Stable Relapsing Multiple Sclerosis
Barnett, Michael
Beadnall, Heidi
Klistorner, Alexander
Sergott, Robert
Greenberg, Benjamin
Rynders, Austin
Ho, Karen
Sepassi, Marjan
Evan, Jacob
Evan, Jeremy
McBride, Ryan
Hartford, Alan
Hotchkin, Michael
NEUROLOGY, 2024, 102 (12) : S12 - S13
[30] Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study
Ralf Gold
Ernst-Wilhelm Radue
Gavin Giovannoni
Krzysztof Selmaj
Eva Kubala Havrdova
Xavier Montalban
Dusan Stefoski
Till Sprenger
Randy R. Robinson
Sami Fam
Jonathan Smith
Spyros Chalkias
Giorgio Giannattasio
Gabriel Lima
Wanda Castro-Borrero
Journal of Neurology, 2020, 267 : 2851 - 2864

← 1 2 3 4 5 →